Banque Cantonale Vaudoise Acquires Shares of 3,728 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Key Points

• Banque Cantonale Vaudoise acquired 3,728 shares of Alnylam Pharmaceuticals, valued at approximately $1,007,000, during the first quarter of the year.
• Alnylam Pharmaceuticals reported a negative earnings per share of ($0.51) for the last quarter, missing analysts' expectations, although it achieved revenues of $773.69 million, exceeding estimates.
• Equities analysts have given Alnylam a consensus rating of "Moderate Buy" with an average target price of $354.96, reflecting strong institutional interest in the stock.

Banque Cantonale Vaudoise bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 3,728 shares of the biopharmaceutical company's stock, valued at approximately $1,007,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Investment Management Corp of Ontario grew its position in Alnylam Pharmaceuticals by 0.6% during the fourth quarter. Investment Management Corp of Ontario now owns 7,099 shares of the biopharmaceutical company's stock valued at $1,670,000 after purchasing an additional 40 shares in the last quarter. Brevan Howard Capital Management LP raised its holdings in shares of Alnylam Pharmaceuticals by 3.4% during the fourth quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company's stock worth $314,000 after acquiring an additional 44 shares in the last quarter. Lindbrook Capital LLC boosted its position in Alnylam Pharmaceuticals by 9.2% during the first quarter. Lindbrook Capital LLC now owns 596 shares of the biopharmaceutical company's stock valued at $161,000 after purchasing an additional 50 shares during the last quarter. SYM FINANCIAL Corp grew its stake in Alnylam Pharmaceuticals by 5.3% in the first quarter. SYM FINANCIAL Corp now owns 1,014 shares of the biopharmaceutical company's stock valued at $274,000 after purchasing an additional 51 shares in the last quarter. Finally, Ballentine Partners LLC grew its stake in Alnylam Pharmaceuticals by 3.3% in the first quarter. Ballentine Partners LLC now owns 1,625 shares of the biopharmaceutical company's stock valued at $439,000 after purchasing an additional 52 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Stock Performance

ALNY traded up $9.56 on Friday, hitting $401.80. 1,780,984 shares of the stock traded hands, compared to its average volume of 1,028,799. The business has a fifty day moving average price of $318.24 and a two-hundred day moving average price of $278.80. The company has a current ratio of 3.04, a quick ratio of 2.98 and a debt-to-equity ratio of 8.88. The firm has a market capitalization of $52.39 billion, a PE ratio of -162.67 and a beta of 0.25. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $402.43.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The firm had revenue of $594.19 million during the quarter, compared to analyst estimates of $584.32 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 444.38%. The business's revenue for the quarter was up 20.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.16) earnings per share. On average, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Wells Fargo & Company lifted their price target on Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the company an "equal weight" rating in a report on Friday. Chardan Capital raised their price objective on shares of Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the company a "buy" rating in a research report on Friday. BMO Capital Markets lifted their target price on shares of Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the company an "outperform" rating in a research note on Tuesday, June 24th. JPMorgan Chase & Co. upped their price objective on shares of Alnylam Pharmaceuticals from $338.00 to $348.00 and gave the stock an "overweight" rating in a report on Wednesday, July 16th. Finally, Morgan Stanley raised their target price on Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the company an "equal weight" rating in a report on Friday. One analyst has rated the stock with a sell rating, three have given a hold rating and twenty-three have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $392.13.

Insider Activity at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 31,640 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, May 30th. The shares were sold at an average price of $304.39, for a total transaction of $9,630,899.60. Following the sale, the chief executive officer directly owned 48,948 shares in the company, valued at approximately $14,899,281.72. The trade was a 39.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.